The pharmaceutical industry is no longer defined—or confined—by borders. Manufacturers are sourcing ingredients, materials, finished products, and contract packaging and manufacturing from around the world, and most are seeking to serve patients in multiple markets. The resulting supply chain is a complex one.
“Things are changing,” says Brian Johnson, senior director, supply-chain security, Pfizer Inc. “Markets are expanding, and where we are sourcing materials and manufacturing is changing.”
NEW YORK, N.Y. – Pfizer Inc. announced today that it has voluntarily recalled 14 lots of Lo/Ovral-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market. An investigation by Pfizer found that some blister packs may contain an inexact count of inert or active ingredient tablets and that the tablets may be out of sequence.
This week Endo Pharmaceuticals reported that several of its products may experience a "constraint" or "disruption" in supply following the temporary shutdown of Novartis Consumer Health Inc.'s Lincoln, NE, manufacturing facility, where these Endo drugs have been manufactured.
Cryopak, the leader in temperature controlled products, announces the launch of their new TimeSaver 24 CRT Mini, the first release in its line of controlled room temperature shipper products.
Plan now to visit Pharmapack Europe in Paris February 15-16. For more details on the event, visit www.pharmapack.fr. Hope to see you stop by the PMP News booth!
Wednesday
15th February 2012
9.30: Opening Address
“From Mesopotamia to modern times, THINK DIFFERENT about INNOVATION,” Patrice Noailles, Président, Seillans Investissement, France
We are pleased to announce that three packaging professionals have joined our Editorial Advisory Board:
Michael Forehand, Principal Packaging Engineer, Global Engineering and Technology, AstraZeneca Pharmaceuticals;
Dan Penny, Director of Packaging Engineering, Cardinal Health;
and Edward M. Dunn, Senior Director Packaging Technology, Merck Manufacturing Division.
America's biopharmaceutical research companies are developing 901 biotechnology medicines and vaccines to address cancer, arthritis, diabetes, and other debilitating and life-threatening diseases, reports the Pharmaceutical Research and Manufacturers of America (PhRMA). These include 353 for cancer and related conditions, 187 for infectious diseases, 69 for autoimmune diseases, and 59 for cardiovascular diseases, PhRMA announced in a press release.
Richard A. Bahr
President & CEO
MGS Machine Corp.
Most new packaging equipment can improve your line’s Overall Equipment Effectiveness (OEE) compared with that of existing, less modern lines. In almost every case, machine manufacturers have stepped up their offerings in machine diagnostics, rapid/repeatable changeovers, and flexibility. Sure, all manufacturers’ offerings are not the same, but you will find most new equipment to be more efficient than past machines.
A new system launched in Brazil at FCE Pharma is designed to offer a stand-alone solution to support different approaches to pharmaceutical product serialization. VisioCIT can handle either labeling or direct coding, reports Christoph Lehmann, director of Uhlmann VisioTec GmbH (www.visiotecamerica.com), which can position companies to meet Brazil’s pending rules as well as others around the world.
At the annual meeting of Pharmaceutical Research and Manufacturers of America (PhRMA), Christopher Viehbacher, chief executive officer of sanofi-aventis, resumed his role as board chairman, while John C. Lechleiter, Ph.D., chairman, president, and chief executive officer of Eli Lilly and Co. was elected as chairman-elect of the PhRMA Board of Directors and Robert J. Hugin, president and chief executive officer of Celgene Corp. was elected PhRMA’s board treasurer. Viehbacher assumed the chairmanship in December 2010.